Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Britain Courts Anthropic Amid US Defense Department Dispute 
BURLINGTON, Mass., Aug. 01, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its second-quarter 2017 financial results on Tuesday, August 8, 2017, at 4:30 p.m. ET.
The dial-in number for the conference call is (855) 770-0022 for domestic participants and (908) 982-4677 for international participants, with Conference ID #56227594. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online following the call.
About Flexion Therapeutics
Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The company’s core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the Boston Business Journal’s 2017 Best Places to Work.
Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
